<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Interesting articles wrt treatment for Metastatic Castration – Resistant Prostate Cancer.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'><br><b>Subject:</b> Fwd: Fw: Radium-223 Treatment for mCRPC<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><p class=MsoNormal>FYI From <a href="http://urotoday.com">urotoday.com</a><o:p></o:p></p><div><div><div><div><div><div><p class=MsoNormal style='background:white'><span style='font-family:"Arial","sans-serif";color:black'> <br><b>Subject:</b> Radium-223 Treatment for mCRPC</span><span style='font-family:"Helvetica","sans-serif";color:black'><o:p></o:p></span></p></div><div><p class=MsoNormal style='background:white'><span style='font-family:"Helvetica","sans-serif";color:black'><o:p> </o:p></span></p><div><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:whitesmoke'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=728 style='width:546.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='mso-line-height-alt:0pt'><a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=37662&mailid=2518&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=728 height=90 id="_x0000_i1025" src="http://digitalscience.rotator.hadj1.adjuggler.net/servlet/ajrotator/1576513/0/vc?z=digitalscience&dim=1387992&kw=&click=&session=no&ajkey="></span></a><o:p></o:p></p></td></tr></table></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt'><tr><td style='background:white;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='mso-line-height-alt:0pt'><a href="http://www.urotoday.com/index.php?option=com_content&Itemid=101&id=49023&lang=en&view=article" target="_blank"><span style='text-decoration:none'><img border=0 width=600 height=100 id="_x0000_i1026" src="http://www.urotoday.com/images/spotlight/Spotlight_header_600x100.jpg" alt="spotlight header"></span></a><o:p></o:p></p></td></tr><tr><td valign=top style='background:white;padding:11.25pt 3.0pt 0cm 3.0pt'><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:19.5pt;color:#6B6B6B'>mCRPC Treatment Exclusives<o:p></o:p></span></p></div><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;color:#6B6B6B'>March 18, 2015<o:p></o:p></span></p></div><div class=MsoNormal align=center style='text-align:center'><hr size=2 width="100%" align=center></div></td></tr><tr><td style='background:white;padding:18.75pt 1.5pt 1.5pt 1.5pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=520 style='width:390.0pt'><tr><td style='border-top:none;border-left:solid #279787 1.0pt;border-bottom:none;border-right:solid #279787 1.0pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:0pt'><img border=0 width=518 height=93 id="_x0000_i1028" src="cid:image001.jpg@01D062E0.CF0BAE70" alt="urology tube"><o:p></o:p></p></td></tr><tr><td valign=top style='border:solid #279787 1.0pt;border-top:none;background:white;padding:15.0pt 15.0pt 15.0pt 15.0pt'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=480 style='width:360.0pt'><tr><td style='background:#EF623E;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center;line-height:130%'><span style='font-size:15.0pt;line-height:130%;color:white'>Charles J. Ryan, MD<o:p></o:p></span></p></div></td></tr><tr><td valign=top style='border:solid #EF623E 1.0pt;background:white;padding:11.25pt 11.25pt 11.25pt 11.25pt'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=450 style='width:337.5pt'><tr><td width=100 style='width:75.0pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='mso-line-height-alt:0pt'><a href="http://www.urotoday.com/index.php?category_id=1506&Itemid=1594&option=com_hwdmediashare&view=mediaitem&id=494&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='text-decoration:none'><img border=0 width=80 height=80 id="_x0000_i1029" src="cid:image002.png@01D062E0.CF0BAE70" alt="c. ryan"></span></a><o:p></o:p></p></td><td width=350 style='width:262.5pt;padding:0cm 0cm 0cm 0cm'><div><p class=MsoNormal style='line-height:140%'><span style='color:#AE472D'>Effects of Ra-223 with Docetaxel vs. Docetaxel on PSA and Bone Alkaline Phosphatase in Patients with CRPC and Bone Metastases<o:p></o:p></span></p></div></td></tr></table></div></td></tr><tr><td style='padding:9.0pt 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=135 style='width:101.25pt'><tr><td style='background:#AE472D;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?category_id=1506&Itemid=1594&option=com_hwdmediashare&view=mediaitem&id=494&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Watch Video →</span></a><o:p></o:p></p></div></td></tr></table></div></td></tr><tr><td style='padding:9.0pt 0cm 0cm 0cm'><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.5pt;line-height:140%;color:#585857'>Charles Ryan, MD presents the results of a study which has shown that the combination of radium-223 plus docetaxel appears to favorably impact posttreatment PSA and bone alkaline phosphatase decline in CRPC patients.<o:p></o:p></span></p></div></td></tr></table></td></tr></table></div></td></tr></table></td></tr></table></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=520 style='width:390.0pt'><tr><td style='background:#49AE7D;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center;line-height:130%'><span style='font-size:15.0pt;line-height:130%;color:white'>Beyond the Abstract<o:p></o:p></span></p></div></td></tr><tr><td valign=top style='border:solid #49AE7D 1.0pt;background:white;padding:15.0pt 15.0pt 15.0pt 15.0pt'><p class=MsoNormal style='margin-bottom:12.0pt'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78296&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='text-decoration:none'><img border=0 width=480 height=100 id="_x0000_i1030" src="cid:c1295d3fd748d5aa7b92cfb390b0dde6" alt="mds meeting"></span></a><o:p></o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td style='padding:0cm 0cm 0cm 0cm'><div><p class=MsoNormal style='line-height:140%'><span style='color:#2D5441'>The use of radium 223 dichloride in a multidisciplinary approach for treating metastatic castration-resistant prostate cancer, by Elisa Borsò<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#3C7258;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78296&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=520 style='width:390.0pt'><tr><td style='background:#57ADEC;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center;line-height:130%'><span style='font-size:15.0pt;line-height:130%;color:white'>2015 GU Cancers Symposium Highlights<o:p></o:p></span></p></div></td></tr><tr><td valign=top style='border:solid #57ADEC 1.0pt;background:white;padding:15.0pt 15.0pt 15.0pt 15.0pt'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='margin-bottom:12.0pt'><a href="http://www.urotoday.com/gu-cancers-symposium-2015/gu-cancers-symp-2015-mcrpc-radiotherapy.html?utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='text-decoration:none'><img border=0 width=480 height=69 id="_x0000_i1031" src="cid:image003.jpg@01D062E0.CF0BAE70" alt="2015 asco gu"></span></a><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#12619B'>Effects of Ra-223 with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with CRPC and bone metastases<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#12619B;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78723&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table><p class=MsoNormal style='margin-bottom:12.0pt'><br><br><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#12619B'>External beam radiation therapy use and safety with Ra-223 in patients with CRPC and symptomatic bone metastases from the ALSYMPCA trial<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#12619B;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78714&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table><p class=MsoNormal style='margin-bottom:12.0pt'><br><br><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#12619B'>Contemporary use of Ra-223 in men with mCRPC<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#12619B;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78754&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table><p class=MsoNormal style='margin-bottom:12.0pt'><br><br><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#12619B'>Ra-223 in U.S. Expanded Access Program (EAP)<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#12619B;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78765&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table><p class=MsoNormal style='margin-bottom:12.0pt'><br><br><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#12619B'>3-year safety follow-up of Ra-223 in patients with CRPC and symptomatic bone metastases from ALSYMPCA<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#12619B;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=1912&option=com_content&view=article&catid=1606&id=78730&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><br> <o:p></o:p></p></td></tr><tr><td style='border:solid #80929E 1.0pt;background:#80929E;padding:11.25pt 0cm 5.25pt 0cm'><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=37650&mailid=2518&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1032" src="cid:10e354c32be72619fa8cc663f93029d8" alt=twitter></span></a> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=37651&mailid=2518&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1033" src="cid:3d31e488c1661908628ece569cffd49c" alt=facebook></span></a> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=37652&mailid=2518&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1034" src="cid:fdff0e671376f4630e2ee9c934c3cb3b" alt=linkedin></span></a> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=37653&mailid=2518&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1035" src="cid:479b26af0c790ab4b716c3873e4ba30f" alt=youtube></span></a> <o:p></o:p></p></td></tr><tr><td style='border:solid #80929E 1.0pt;background:#80929E;padding:0cm 0cm 0cm 0cm'><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;color:white'>UroToday - 2217 Fifth Street, Berkeley, CA 94710 USA<o:p></o:p></span></p></div></td></tr><tr><td style='border:solid #80929E 1.0pt;background:#80929E;padding:3.75pt 0cm 6.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?option=com_acymailing&ctrl=archive&task=view&mailid=2518&key=VH5Rw7Wt&subid=13579-e9ca2e4efd9e5bfe9e07c9e19072ee54&tmpl=component&Itemid=1448&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>View Email in Browser |</span></a> <o:p></o:p></p></td><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'> <a href="http://www.urotoday.com/index.php?option=com_acymailing&view=user&layout=modify&Itemid=101" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>Manage Preferences |</span></a> <o:p></o:p></p></td><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=user&task=out&mailid=2518&key=e9ca2e4efd9e5bfe9e07c9e19072ee54&Itemid=1448" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>Unsubscribe</span></a> <span style='font-size:9.0pt;color:white'>|</span> <o:p></o:p></p></td><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'> <a href="http://www.urotoday.com/index.php?option=com_acymailing&ctrl=archive&task=forward&mailid=2518&key=VH5Rw7Wt&subid=13579-e9ca2e4efd9e5bfe9e07c9e19072ee54&Itemid=1448&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>Forward Email</span></a> <o:p></o:p></p></td></tr></table></div></td></tr><tr><td style='background:whitesmoke;padding:7.5pt 3.75pt 7.5pt 3.75pt'><p class=MsoNormal><span style='font-size:7.5pt'>You are receiving this email because you have chosen to receive emails from UroToday. <a href="http://www.urotoday.com/index.php?option=com_comprofiler&Itemid=473&utm_source=newsletter_2518&utm_medium=email&utm_campaign=radium-223-treatment-for-mcrpc-031815&acm=13579_2518" target="_blank"><b><span style='color:#4687E9;text-decoration:none'>Log in</span></b></a> to update your email address or view your email preferences. If you have any questions about your account, please log in to contact us securely and we will be happy to assist you.<o:p></o:p></span></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal style='background:white'><span style='font-family:"Helvetica","sans-serif";color:black'><img border=0 width=1 height=1 id="_x0000_i1036" src="https://fzi9fqc4.emltrk.com/fzi9fqc4?d=rochab2@yahoo.com"><img border=0 width=50 height=1 id="_x0000_i1037" src="http://www.urotoday.com/index.php?option=com_acymailing&ctrl=stats&mailid=2518&subid=13579&Itemid=1448"><o:p></o:p></span></p></div></div><p class=MsoNormal style='margin-bottom:12.0pt;background:white'><span style='font-family:"Helvetica","sans-serif";color:black'><o:p> </o:p></span></p></div></div></div></div></div></div><p class=MsoNormal><o:p> </o:p></p></div></div></body></html>